|
|
|
Dr
Philip G. Stimpson MIREE - Chief
Executive Officer
Philip is a qualified electronic
engineer and has been involved
in the medical industry for 35
years, having started work in
Canada and the USA in sales and
marketing. In the UK Philip founded
P.G.S. Medical, a sales and distribution
company which was successfully
sold to Gould Group Inc. in 1977.
Philip subsequently founded Medix
Limited in 1978, to design, manufacture
and distribute drug delivery
systems for asthma sufferers.
Philip was awarded four SMART
awards for research and development
in this company. Medix Ltd was
sold to Bespak plc in 1993 following,
which, Philip founded Mediwatch
Limited in 1996 where he gained
a further two SMART awards and
one European award for Research
and Development into diagnostic
products. Philip is a founding
director and shareholder of Mediwatch
Plc.
|
|
Click
here to view quote |
|
|
Mr
Colm T. Croskery FCA B,Comm
MBA - CFO
Colm is an experienced business
leader with 20 years experience
in building businesses within
the healthcare sector. Within
the last five years, his director
positions were Managing Director
of White Rose Environmental
Ltd. and White Rose Environmental
Sharpsmart Ltd. (both subsidiaries
of Stericycle Inc.). He was
also CEO of Medical Support
Systems and held senior positions
within Huntleigh Technology
plc and Hill-Rom Inc. Colm
has had extensive experience
in driving rapid growth, through
acquisitions and organically,
in medical device businesses
in fast changing environments.
Colm has been with Mediwatch
since July 2007, initially
joining in a part-time capacity
as Operations Manager, becoming
a full-time employee in January
2008. Colm joined the Board in May 2008.
|
|
Click here to view quote |
|
|
Dr Marcus Harrison - Chief Scientific Officer
Marcus joined Mediwatch in January 2009. He has a broad technical background across biomedical, life and physical sciences, including diagnostics, genomics and drug and vaccine development. He
primarily worked in small to medium biotechnology companies developing products and services.
Before moving to Mediwatch Marcus worked for Oxford Gene Technology where he held technical, programme and product manager positions.
Following his PhD he spent a number of years in food research understanding. interactions between food components and flavour. Marcus holds a PhD in Theoretical Physics and BSc in Physics, both from The University of Sheffield.
|
|
 |
|
|
|
|
|
|
Non - Executive
Directors |
|
|
|
|
Mr
Omer M. A. Karim MB BS MS FRCS
FRCSUrol - Non-Executive
Chairman
Omer is a Consultant Urological Surgeon
at St Mary s Hospital, Paddington and
Heatherwood and Wexham Park NHS Hospitals
Trust. Omer qualified at Charing Cross
Hospital Medical School, London in
1982 and has been a consultant since
1995. Omer carried out research for
his Mastership of Surgery whilst he
was a Fellow at the Brady Urological
Institute, The Johns Hopkins Hospital,
Baltimore, Maryland, USA. He is also
a Director of Oldfield Lodge Medical
Practice Limited and Robotic Urological
Surgery Limited. He is interested in
the diagnosis and treatment of prostate
cancer. Omer is a founding director
and shareholder of Mediwatch Plc. He
became Non-Executive Chairman in April
2007. Omer
is a member of the Salaries and Remuneration
Committee.
|
|
Click here to view quote |
|
|
Mr
Charles E. Cattaneo BCom(Hons)
MBA FSI CF FCA - Non-Executive
Director
Charles is a fellow of the Institute
of Chartered Accountants in England and
Wales, a Fellow of the Securities and
Investment Institute and has an MBA from
Birmingham University where he also read
Commerce. He has over 20 years corporate
finance experience, in investment banking,
industry and the profession. He is a
Partner of Cattaneo LLP where
he specialises in providing corporate
finance advice to a wide range of clients
including Listed, AIM and private companies.
He was previously at Grant Thornton and at KPMG
Corporate Finance where he held the post
of Partner with responsibility for providing
financial advice to listed public companies
and large/growing private companies.
Charles is Chairman of the London Stock
Exchange’s Midlands Regional Advisory
Group. Charles joined the Board in May
2007. Charles is Chairman of the Audit Committee.
|
|
Click here to view quote |
|
|
Professor
Mark Emberton MB BS MD FEBU FRCS
FRCSUrol - Non-Executive
Medical Director
Mark is Reader in Interventional Oncology
at University College London, Honorary
Consultant Urologist at University
College London Hospitals NHS Foundation
Trust and is Clinical Director of the
Clinical Effectiveness Unit at the
Royal College of Surgeons of England
Mark is an active researcher in the
area of prostate cancer and benign
prostatic hyperplasia. He has published
over 100 peer review papers in scientific
journals and is a regular invited speaker
at international meetings. Mark sits
on advisory boards for a number of
major pharmaceutical companies. His
sits on the Partner s Council at the
National Institiute of Clinical Excellence
and on the Interventional Procedures
Panel of the Health Technology Assessment
arm of the Department of Health. Mark
is a founding director and shareholder
of Mediwatch Plc. Mark is Chairman of the Salaries and Remuneration Committee.
|
|
 |
|
|
|
|
|
|
|
The
Company, follows and so far is practicable
and appropriate for a smaller public
company, complies with the principles
of good governance and the code of
best practice prepared by the Committee
on Corporate Governance and published
in June 1998. The Company has adopted
the Model Code for AIM companies.
An Audit committee has been established
which is composed of the Company's non-executive
Directors and finance Director. It meets
at least twice each year and is charged
with making recommendations to the Board
on the appointment of auditors and the
audit fee, for reviewing the conduct and
control of the annual audit and for reviewing
the operation of the internal financial
controls. It also has the responsibility
for the proper reporting of the financial
performance of the Group and for reviewing
financial statements prior to publication.
At least one meeting a year takes place
with the auditors without the executive
Board members being present.
A Salaries and Remuneration Committee
has been established which is composed
of the Company's non-executive Directors. It reviews
the performance of the executive Directors
and sets the scale and structure of their
remuneration and the basis of their service
agreements with due regard to the interests
of shareholders. It also determines the
allocation of share options to employees.
Non-executive Directors' remuneration is
reviewed by the Board as a whole.
|
|
|
|
|
|
|
